QSYMIA (Phentermine-Topiramate) Drug Insights and Market Forecasts to 2032

2023-01-03

DUBLIN, Jan. 3, 2023 /PRNewswire/ -- The "QSYMIA (Phentermine-Topiramate), Drug Insight and Market Forecast - 2032" report has been added to

ResearchAndMarkets.com's offering.

The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities.

Further, it also consists of future market assessments inclusive of the QSYMIA (Phentermine- topiramate) market forecast, analysis for Obesity in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Obesity.

Drug Summary

QSYMIA, previously known as Qnexa, is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate extended-release, an antiepileptic drug.

It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial Body Mass Index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.

The recommended dosage regimen of QSYMIA is 3.75 mg/23 mg (phentermine 3.75 mg/topiramate 23 mg extended-release) daily for 14 days; then increase to 7.5 mg/46 mg daily. Discontinue or escalate dosage if 3% weight loss is not achieved after 12 weeks on a 7.5 mg/46 mg dose or if 5% weight loss is not achieved after 12 weeks on a maximum daily dose of 15 mg/92 mg.

Phentermine is a sympathomimetic amine with pharmacologic activity similar to amphetamine (d- and d/l-amphetamine), the prototype drug of this class used in obesity. Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics."

The effect of phentermine on chronic weight management is likely mediated by the release of catecholamines in the hypothalamus, resulting in reduced appetite and decreased food consumption, but other metabolic effects may also be involved. The exact mechanism of action is not known.

The precise mechanism of action of topiramate on chronic weight management is not known. Topiramate's effect on chronic weight management may be due to its effects on both appetite suppression and satiety enhancement, induced by a combination of pharmacologic effects, including augmenting the activity of the neurotransmitter gamma-aminobutyrate, modulation of voltage-gated ion channels, inhibition of AMPA/kainite excitatory glutamate receptors, or inhibition of carbonic anhydrase.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the QSYMIA (Phentermine- topiramate) description, mechanism of action, dosage and administration, research and development activities in Obesity.

Elaborated details on QSYMIA (Phentermine- topiramate) regulatory milestones and other development activities have been provided in this report.

The report also highlights the QSYMIA (Phentermine- topiramate) research and development activity in Obesity in detail across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around QSYMIA (Phentermine- topiramate).

The report contains forecasted sales of QSYMIA (Phentermine- topiramate) for Obesity till 2032.

Comprehensive coverage of the late-stage emerging therapies for Obesity.

The report also features the SWOT analysis with analyst views for QSYMIA (Phentermine- topiramate) in Obesity.

Report Highlights

In the coming years, the market scenario for Obesity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence QSYMIA (Phentermine- topiramate) dominance.

Other emerging products for Obesity are expected to give tough market competition to QSYMIA (Phentermine- topiramate) and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of QSYMIA (Phentermine- topiramate) in Obesity.

The in-depth analysis of the forecasted sales data of QSYMIA (Phentermine- topiramate) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the QSYMIA (Phentermine- topiramate) in Obesity.

Key Questions Answered

What is the product type, route of administration and mechanism of action of QSYMIA (Phentermine- topiramate)?

What is the clinical trial status of the study related to QSYMIA (Phentermine- topiramate) in Obesity and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the QSYMIA (Phentermine- topiramate) development?

What are the key designations that have been granted to QSYMIA (Phentermine- topiramate) for Obesity?

What is the forecasted market scenario of QSYMIA (Phentermine- topiramate) for Obesity?

What are the forecasted sales of QSYMIA (Phentermine- topiramate) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Obesity and how are they giving competition to QSYMIA (Phentermine- topiramate) for Obesity?

Which are the late-stage emerging therapies under development for the treatment of Obesity?

Key Topics Covered:

1. Report Introduction

2. QSYMIA (Phentermine - topiramate) Overview

2.1. Product Detail

2.2. Clinical Development

2.2.1. Clinical Studies

2.2.2. Clinical Trials Information

2.2.3. Safety and Efficacy

2.3. Regulatory Milestones

2.4. Other Developmental Activities

2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape ( Emerging Therapies) *

5. QSYMIA (Phentermine - topiramate) Market Assessment

5.1. Market Outlook of QSYMIA (Phentermine - topiramate) in Obesity

5.2. 7MM Market Analysis

5.2.1. Market Size of QSYMIA (Phentermine - topiramate) in the 7MM for Obesity

5.3. Country-wise Market Analysis

5.3.1. Market Size of QSYMIA (Phentermine - topiramate) in the United States for Obesity

5.3.2. Market Size of QSYMIA (Phentermine - topiramate) in Germany for Obesity

5.3.3. Market Size of QSYMIA (Phentermine - topiramate) in France for Obesity

5.3.4. Market Size of QSYMIA (Phentermine - topiramate) in Italy for Obesity

5.3.5. Market Size of QSYMIA (Phentermine - topiramate) in Spain for Obesity

5.3.6. Market Size of QSYMIA (Phentermine - topiramate) in the United Kingdom for Obesity

5.3.7. Market Size of QSYMIA (Phentermine - topiramate) in Japan for Obesity

6. SWOT Analysis

7. Analysts' Views

8. Appendix

9. Publisher Capabilities

10. Disclaimer

11. About the Publisher

12. Report Purchase Options

For more information about this report visit https://www.researchandmarkets.com/r/wxh1kw

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets